RxDoctor Payments Data

Myacinth Pineda, APRN

Family · Las Vegas, NVNPI 1578152922

Payments from drug & device makers

$1,957in general payments, 2019–2025

Across 83 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$332
  • Boehringer Ingelheim$295
  • Amgen$211
  • Veloxis Pharmaceuticals, Inc.$162
  • AstraZeneca$111
  • Otsuka America Pharmaceutical, Inc.$106
  • plus $740 from 14 others

What the payments were for

  • Food & beverage$1,81593%
  • Education$1417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,957 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$77,791
Medicare patients
250
Services billed
2,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate32$26,131
Cinacalcet Hcl114$17,410
Valganciclovir Hcl25$15,350
Tacrolimus43$9,617
EliquisApixaban12$6,501
Mycophenolate Mofetil34$4,231
Nifedipine ErNifedipine70$2,138
K-Phos OriginalPotassium Phosphate,monobasic13$1,292
Fluconazole22$1,145
Leflunomide12$1,130
Prednisone136$1,013
Hydralazine Hcl76$889
Famotidine52$773
Carvedilol81$768
Doxazosin Mesylate24$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$111$26,13132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →